|
1
|
Rottmann M, Burges A, Mahner S, Anthuber
C, Beck T, Grab D, Schnelzer A, Kiechle M, Mayr D, Pölcher M, et
al: Cancer of the ovary, fallopian tube, and peritoneum: A
population-based comparison of the prognostic factors and outcomes.
J Cancer Res Clin Oncol. 143:1833–1844. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doubeni CA, Doubeni AR and Myers AE:
Diagnosis and management of ovarian cancer. Am Fam Physician.
93:937–944. 2016.PubMed/NCBI
|
|
4
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoskins PJ and Gotlieb WH: Missed
therapeutic and prevention opportunities in women with BRCA-mutated
epithelial ovarian cancer and their families due to low referral
rates for genetic counseling and BRCA testing: A review of the
literature. CA Cancer J Clin. 67:493–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cech TR and Steitz JA: The noncoding RNA
revolution-trashing old rules to forge new ones. Cell. 157:77–94.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitz SU, Grote P and Herrmann BG:
Mechanisms of long noncoding RNA function in development and
disease. Cell Mol Life Sci. 73:2491–2509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huarte M, Guttman M, Feldser D, Garber M,
Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M,
et al: A large intergenic noncoding RNA induced by p53 mediates
global gene repression in the p53 response. Cell. 142:409–419.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duan H, Li X, Chen Y, Wang Y and Li Z:
LncRNA RHPN1-AS1 promoted cell proliferation, invasion and
migration in cervical cancer via the modulation of miR-299-3p/FGF2
axis. Life Sci. 239:1168562019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding L, Wang L, Li Z, Jiang X, Xu Y and
Han N: The positive feedback loop of RHPN1-AS1/miR-1299/ETS1
accelerates the deterioration of gastric cancer. Biomed
Pharmacother. 124:1098482020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Yan Z, Wang L, Zhang S and Gao M:
STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor
prognosis of hepatocellular carcinoma and contributes to tumor
progression via the miR-485/CDCA5 axis. J Cell Biochem. Feb
17–2020.(Epub ahead of print).
|
|
14
|
Zheng W, Li H, Zhang H, Zhang C, Zhu Z,
Liang H and Zhou Y: Long noncoding RNA RHPN1-AS1 promotes
colorectal cancer progression via targeting miR-7-5p/OGT axis.
Cancer Cell Int. 20:542020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng S, Lv P, Su J, Miao K, Xu H and Li
M: Silencing of the long non-coding RNA RHPN1-AS1 suppresses the
epithelial-to-mesenchymal transition and inhibits breast cancer
progression. Am J Transl Res. 11:3505–3517. 2019.PubMed/NCBI
|
|
16
|
Li X, Zhang X, Yang C, Cui S, Shen Q and
Xu S: The lncRNA RHPN1-AS1 downregulation promotes gefitinib
resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell
Cycle. 17:1772–1783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lv H, Hou H, Lei H, Nie C, Chen B, Bie L,
Han L and Chen X: MicroRNA-6884-5p regulates the proliferation,
invasion, and EMT of gastric cancer cells by directly targeting
S100A16. Oncol Res. 28:225–236. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beltrame L, Di Marino M, Fruscio R, Calura
E, Chapman B, Clivio L, Sina F, Mele C, Iatropoulos P, Grassi T, et
al: Profiling cancer gene mutations in longitudinal epithelial
ovarian cancer biopsies by targeted next-generation sequencing: A
retrospective study. Ann Oncol. 26:1363–1371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Erriquez J, Becco P, Olivero M, Ponzone R,
Maggiorotto F, Ferrero A, Scalzo MS, Canuto EM, Sapino A, Verdun di
Cantogno L, et al: TOP2A gene copy gain predicts response of
epithelial ovarian cancers to pegylated liposomal doxorubicin:
TOP2A as marker of response to PLD in ovarian cancer. Gynecol
Oncol. 138:627–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sherman-Baust CA, Kuhn E, Valle BL, Shih
IeM, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, et al:
A genetically engineered ovarian cancer mouse model based on
fallopian tube transformation mimics human high-grade serous
carcinoma development. J Pathol. 233:228–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong S, Wang R, Wang H, Ding Q, Zhou X,
Wang J, Zhang K, Long Y, Lu S, Hong T, et al: HOXD-AS1 promotes the
epithelial to mesenchymal transition of ovarian cancer cells by
regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res.
38:1102019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shahab SW, Matyunina LV, Mezencev R,
Walker LD, Bowen NJ, Benigno BB and McDonald JF: Evidence for the
complexity of microRNA-mediated regulation in ovarian cancer: A
systems approach. PLoS One. 6:e225082011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Edgar R, Domrachev M and Lash AE: Gene
Expression Omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Yang T, Ji J, Zhao F, Li C and Han
X: RHPN1-AS1 promotes cell proliferation and migration via
miR-665/Akt3 in ovarian cancer. Cancer Gene Ther. 28:33–41. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Ding W, Xu Y, Tao E, Mo M, Xu W,
Cai X, Chen X, Yuan J and Wu X: Long non-coding RNA RHPN1-AS1
promotes tumorigenesis and metastasis of ovarian cancer by acting
as a ceRNA against miR-596 and upregulating LETM1. Aging (Albany
NY). 12:4558–4572. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tao F, Tian X, Lu M and Zhang Z: A novel
lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and
migration by sponging miR-34a and miR-34c. J Genet Genomics.
45:137–145. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zou MF, Ling J, Wu QY and Zhang CX: Long
non-coding RNA PVT1 functions as an oncogene in ovarian cancer via
upregulating SOX2. Eur Rev Med Pharmacol Sci. 22:7183–7188.
2018.PubMed/NCBI
|
|
33
|
Wang Q, Li XP, Zhou X, Yang CF and Zhu Z:
A single-nucleotide polymorphism in lnc-LAMC2-1:1 interferes with
its interaction with miR-128 to alter the expression of deleted in
colorectal cancer and its effect on the survival rate of subjects
with ovarian cancer. J Cell Biochem. 121:4108–4119. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nuncia-Cantarero M, Martinez-Canales S,
Andres-Pretel F, Santpere G, Ocana A and Galan-Moya EM: Functional
transcriptomic annotation and protein-protein interaction network
analysis identify NEK2, BIRC5, and TOP2A as potential targets in
obese patients with luminal A breast cancer. Breast Cancer Res
Treat. 168:613–623. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Z, Liu Y, Shi C, Zhang Y, Lv R, Zhang
R, Wang Q and Wang Y: Suppression of PTEN/AKT signaling decreases
the expression of TUBB3 and TOP2A with subsequent inhibition of
cell growth and induction of apoptosis in human breast cancer MCF-7
cells via ATP and caspase-3 signaling pathways. Oncol Rep.
37:1011–1019. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pei YF, Yin XM and Liu XQ: TOP2A induces
malignant character of pancreatic cancer through activating
β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis.
1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
